ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2024 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided EPS guidance of 4.260-4.670 for the period, compared to the consensus EPS estimate of 4.470. The company issued revenue guidance of $520.0 million-$542.0 million, compared to the consensus revenue estimate of $534.2 million.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ANIP. Capital One Financial began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an overweight rating and a $80.00 price target on the stock. HC Wainwright upped their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a buy rating in a research note on Monday, March 4th. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a buy rating in a research note on Friday, March 1st. Finally, Guggenheim increased their target price on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a buy rating in a research report on Tuesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of Buy and an average target price of $80.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $65.48 on Monday. The company’s 50 day moving average price is $64.95 and its two-hundred day moving average price is $58.65. ANI Pharmaceuticals has a 12-month low of $36.99 and a 12-month high of $70.81. The firm has a market cap of $1.38 billion, a PE ratio of 77.95 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. Equities research analysts predict that ANI Pharmaceuticals will post 3.55 earnings per share for the current year.

Insider Activity

In other news, CEO Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at $29,155,155.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at $29,155,155.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen P. Carey sold 7,787 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.55, for a total transaction of $510,437.85. Following the transaction, the chief financial officer now directly owns 177,712 shares in the company, valued at $11,649,021.60. The disclosure for this sale can be found here. Insiders sold 139,994 shares of company stock worth $9,268,023 over the last three months. 12.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in ANI Pharmaceuticals by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock worth $71,074,000 after acquiring an additional 156,594 shares during the period. Wellington Management Group LLP purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $514,000. Goldman Sachs Group Inc. grew its stake in ANI Pharmaceuticals by 5.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 41,201 shares of the specialty pharmaceutical company’s stock worth $2,272,000 after buying an additional 2,007 shares in the last quarter. GSA Capital Partners LLP purchased a new position in ANI Pharmaceuticals in the 4th quarter worth approximately $516,000. Finally, Chartwell Investment Partners LLC boosted its stake in shares of ANI Pharmaceuticals by 79.6% in the 4th quarter. Chartwell Investment Partners LLC now owns 10,472 shares of the specialty pharmaceutical company’s stock valued at $578,000 after purchasing an additional 4,641 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.